Scroll left and right to see.
Name of project | Research period | Progress and future plan | Otehrs |
---|---|---|---|
KDC-14-1 | 2014 - ongoing |
- Pre-clinical trials (rodents, no rodents) completed. - IND application completed. - Phase 1, and Phase 2 clinical trials plan |
Osteoporosis therapeutic agent |
KDC-16-1 | 2016 - 2018 |
- National project completed (December 2018) - Human application test (gastrointestinal health) completed. - Application for individual certification of material completed and health functional food |
Certification of individual material in functional ingredient for gastrointestinal tract |
KDC-17-2-1 | 2017 - ongoing |
- Selection of valid substances completed - Joint research plan with university hospital for ex vivo (mechanism research) and in vivo (animal test) studies. - Plan to apply for national project for pre-clinical and clinical trials |
Anti-thrombotic combination agent |
KDC-E17-1 | 2017 - ongoing |
- Apply of controlled release technology through patent avoidance - Formulation research ongoing, planned for release 2Q in 2020. |
Muscle relaxant |
KDC-C17-2 | 2017 - ongoing |
- Application of controlled release technology through patent avoidance - Formulation research ongoing, planned for release 3Q in 2020. |
Anti-platelet agent |
KDC-R18-1 | 2018 - ongoing | - In preparation for the dynamic stability test, scheduled for release 1Q in 2020. | Anti-Parkinson's disease drug |
KDC-P18-2 | 2018 - ongoing | - Apply of controlled release technology and remaining system in the gastrointestinal track through patent avoidance. - Formulation research in progress, scheduled for release 4Q in 2022. |
Anti-epilepsy drug |
KDC-D18-3 | 2018 - ongoing | - Apply of double delay release system through patent avoidance - Formulation research in progress, scheduled for release 1Q in 2023. |
Anti-ulcer drug |
Development of diabetic therapeutic substance | 2018 - ongoing | - Exploring candidate substances | - |
Development of muscle atrophy improvement agents | 2018 - ongoing | - Exploring candidate substances | - |
Classification | Department | Major responsibilities |
---|---|---|
Central Research Institute | Research planning Team | - Government project monitoring and new project application. - Progress management of government projects. - Identification of short-term, mid-term, and new project items. - Research document management and management of research support SOP. - Research budget management for government project. - Revision and management of research departments work standard. - Patent analysis and patent strategy establishment. - Patent filing, patent litigation, and litigation management. - Trademark filing, and trademark litigation management. - IP-R&D planning and patent portfolio design. - Establishment of intellectual property management system. |
Formulation Research Team | - Review and analysis of patents and papers for improved drug candidates for formulation. - Research and validation of new formulation technologies to secure formulation efficacy. - Research and product development of new formulation source technologies - Pre-formulation work for new substances and improved drug candidates. - Research on pharmaceutical process improvement and support for clinical trial drug production. |
|
Pharmacology Research Team | - Evaluation of activity and efficacy of new substances. - Safety evaluation of active compounds. - Establishment and implementation of animal model to secure efficacy. - Establishment and implementation of in vitro/ in vivo evaluation system for PoC validation. - Lead research and conduct of non-clinical trial studies. - Toxicity studies for new drug candidates. |
Category | Project name | Research title | Research period | Total research budget |
---|---|---|---|---|
Ministry of agriculture, food and rural affairs | Agricultural industry technology developmental service | Development and industrialization of osteoporosis treatment food and medicinal materials using common sate. | July 20, 2014 - July 28, 2019 (5 years) | Approximately 6.66 billion KRW |
High Value food technology development project | Development and commercialization of natural ingredients for controlling atopic dermatitis aggravating factor. | Nov. 28, 2014 - Nov. 27, 2017 (3 years) | 1.2 billion KRW | |
Development of novel functional food ingredients using portulaca extract | July 7, 2016 - Dec. 31, 2018 (3 years) | Approximately 760 million KRW |